Effect of Soluble Dietary Fiber on Bacterial Translocation in Crohn's Disease
NCT02164877 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 3
Last updated 2018-04-17
Summary
The purpose of this study is to evaluate the effect of soluble dietary fiber on bacterial translocation and mucosal immunology in patients with Crohn's disease.
Conditions
Interventions
- DRUG
-
pectin
Patients allocated to experiment group will receive 15g pectin each day
Sponsors & Collaborators
-
Jinling Hospital, China
lead OTHER
Principal Investigators
-
Jianfeng Gong, MD · Department of general surgery,Jinling hospital
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 17 Years
- Max Age
- 40 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-06-30
- Primary Completion
- 2017-05-31
- Completion
- 2017-06-30
Countries
- China
Study Locations
More Related Trials
-
Study of Factors and Mechanisms Influencing the Effects of Treatments in Crohn's Disease
NCT04135027 ·Status: UNKNOWN
-
Effect of Glutamine on Intestinal Permeability in Crohn's Disease
NCT00838149 ·Status: COMPLETED ·Phase: PHASE1
-
Washed Microbiota Transplantation Improves Nutritional Status of Patients With Crohn's Disease
NCT02897661 ·Status: UNKNOWN ·Phase: NA
-
Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease
NCT00032799 ·Status: COMPLETED ·Phase: PHASE3
-
Crohn's Disease Stem Cell Transplantation
NCT00271947 ·Status: TERMINATED ·Phase: PHASE2
-
Efficacy Study of Tripterygium Glycoside Combined With Enteral Nutrition in the Treatment of Crohn's Disease for Induction Remission
NCT01820247 ·Status: UNKNOWN ·Phase: NA
-
Therapeutic Modulation of the Intestinal Creatine Kinase System in Inflammatory Bowel Disease (IBD)
NCT02463305 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
The Impact of "Crohn's Disease-TReatment-with-EATing" Diet and Exclusive Enteral Nutrition on Healthy Gut Bacteria
NCT02426567 ·Status: COMPLETED ·Phase: NA
-
Efficacy of Exclusive Enteral Nutrition in Adult Active Crohn's Disease
NCT02887287 ·Status: COMPLETED
-
Infliximab to Treat Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous Disease
NCT00325078 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Based on the Special Disease Management of Crohn's Disease Diet Studies
NCT04976491 ·Status: UNKNOWN
-
Efficacy of CROWN in Repair and Maintenance of the Intestinal Mucosa in Patients With CD Receiving Anti-TNF Therapy
NCT02793778 ·Status: TERMINATED ·Phase: PHASE2
-
Safety and Efficacy of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease
NCT01203631 ·Status: COMPLETED ·Phase: PHASE2
-
The Effects of Parenteral ω-3 Polyunsaturated Fatty Acid on Postoperative Complications of Patients With Crohn's Disease
NCT03901937 ·Status: UNKNOWN ·Phase: PHASE4
-
Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease
NCT00032786 ·Status: COMPLETED ·Phase: PHASE3
-
Fecal Microbiota Transplantation as the First-line Treatment in Active Pediatric Crohn's Disease
NCT05321758 ·Status: RECRUITING ·Phase: NA
-
Fecal Transplant for Crohn's Disease
NCT03078803 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate Safety, Tolerability and Efficacy of GSK2330811 in Crohn's Disease
NCT04151225 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Crohn's Disease Diet to Reduce Symptoms of Crohn's Disease
NCT01897090 ·Status: WITHDRAWN ·Phase: NA
-
Effect of the Consumption of a Probiotic Strain on the Prevention of Post-operative Recurrence in Crohn's Disease
NCT01698970 ·Status: COMPLETED ·Phase: NA
-
Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease
NCT02914600 ·Status: TERMINATED ·Phase: PHASE3
-
Standardized Fecal Microbiota Transplantation for Crohn's Diseases
NCT01793831 ·Status: RECRUITING ·Phase: NA
-
Preliminary Clinical Study on the Effect of Bacillus Subtilis on the Efficacy of Infliximab in Patients With Crohn's Disease
NCT07123207 ·Status: RECRUITING ·Phase: NA
-
CP-461 for the Treatment of Crohn's Disease
NCT00042055 ·Status: COMPLETED ·Phase: PHASE2
-
Brodalumab (AMG 827) in Adults With Moderate to Severe Crohn's Disease
NCT01150890 ·Status: TERMINATED ·Phase: PHASE2